crestonepharma.com Open in urlscan Pro
2606:4700:20::ac43:459c  Public Scan

Form analysis
0 forms found in the DOM

Text Content

info@crestonepharma.com

 * Follow
 * Follow
 * Follow

 * Company
   * About Us
   * Team
   * Code of Ethics
   * Careers
   * Press Releases
 * Pipeline
   * CRS3123 for C. difficile
   * CRS0540 Gram-positives
   * CRS0393 NTM/TB
 * Knowledge Portal
 * Contact Us
 * 19-0021 Clinical Study

 * Company
   * About Us
   * Team
   * Code of Ethics
   * Careers
   * Press Releases
 * Pipeline
   * CRS3123 for C. difficile
   * CRS0540 Gram-positives
   * CRS0393 NTM/TB
 * Knowledge Portal
 * Contact Us
 * 19-0021 Clinical Study

Breaking the Cycle of Bacterial Growth and Resistance


AN INNOVATIVE BIOTECH COMPANY IN BOULDER, CO.

Crestone is a Boulder, Colorado based clinical stage biopharmaceutical company
developing new drug candidates with entirely novel mechanisms. Our research
pipeline includes: C. diff treatment, antibiotic-resistant Gram-positive
infection treatments, Tuberculosis treatments, and more.

Read More

See our progress


PIPELINE

MORE

Enroll today


CLINICAL STUDIES

MORE

Get the latest news


PRESS RELEASES

MORE

Get to know us


OUR TEAM

MORE


WHO WE ARE



Boulder, Colorado-based Crestone, Inc. is a clinical stage biopharmaceutical
company focused on inventing and developing novel mechanism of action small
molecule drugs for serious bacterial infections. Our pipeline includes
antibacterial agents aiming to treat a variety of serious conditions caused by
antibacterial-resistant microbes, from C. difficile infection to MRSA,
tuberculosis, and more.

MORE ABOUT CRESTONE


OUR PIPELINE



Our R&D pipeline includes several programs that address areas of significant and
growing unmet medical need, such as C. diff infection, all with novel mechanism
of action agents.

LEARN MORE



CLINICAL STUDIES



CLINICAL STUDY 19-0021 | C. DIFF INFECTION TREATMENT

A Randomized, Double-blind Evaluation of CRS3123 Versus Oral Vancomycin in Adult
Patients with Clostridioides difficile Infection. Phase II is enrolling now—find
a clinical site near you and contact the study coordinator to see if you may be
eligible to participate!



Learn More About This Study & Enrollment


KNOWLEDGE PORTAL

WHAT IS YOUR RISK OF DEVELOPING A C. DIFFICILE INFECTION?

Clostridioides difficile is a bacterium that is found in the intestines of
humans and animals and in the environment. Certain strains of this organism can
produce toxins that cause damage...

BROWSE MORE INFORMATION & NEWS


BECOME A PART OF OUR PROJECTS

Interested in helping further our research into novel antibacterial agents? We’d
be thrilled to have your help, either as an investor, a team member, or a
participant in our ongoing clinical studies.


INQUIRIES

Have a question or comment? Follow the link below to contact us about general
inquiries.

Contact Us


CAREERS

Find work in a team-oriented environment at one of the leading Colorado pharma
companies.

Join Crestone


CLINICAL STUDIES

Learn how you can become part of our ongoing clinical study to fight deadly GI
tract infections.

Enroll Today

Copyright © Crestone Inc. 2022. All Rights Reserved. Website by tekRESCUE

Enrollment is Now Open for the 19-0021 Clinical Study

Learn More
×